Source comparison
CJC-1295 40s Age Specific Protocol: Comparison
20s–30s 100mcg Twice weekly (every 3.5 days) 250–350 ng/mL Baseline, Week 8, Week 16 Higher receptor density and insulin sensitivity allow aggressive dosing without metabolic disruption. But most don't need peptides at this age unless clinically deficient. 40s
This comparison does not assign a generated winner or score.
- 20s–30s
- 100mcg
- Twice weekly (every 3.5 days)
- 250–350 ng/mL
- Baseline, Week 8, Week 16
- Higher receptor density and insulin sensitivity allow aggressive dosing without metabolic disruption. But most don't need peptides at this age unless clinically deficient.
- 40s
- 50–75mcg
- 200–280 ng/mL
- Baseline, Week 4, Week 8, then every 8 weeks
- Reduced hepatic GH receptor density means lower doses achieve therapeutic IGF-1 elevation. Overshooting this range increases insulin resistance risk without added anabolic benefit.
- 50s+
- 50mcg
- Once every 4–5 days
- 180–240 ng/mL
- Baseline, Week 4, Week 6, then every 6 weeks
- Further decline in receptor density and increased metabolic fragility require conservative dosing. Risk-benefit ratio favors lower frequency with tighter IGF-1 monitoring.